Australian researchers who used PET with Cu-64 CuCl2 found that mice with neuroblastoma that received the new drug dextran-catechin, which cut copper supply to tumors, had significantly reduced tumor growth without a corresponding drop in blood copper levels. The findings in the journal Theranostics suggest that Cu-64 CuCl2 PET may be used to provide personalized cancer treatments and improve cancer drug resistance awareness, researchers said.
PET study evaluates breakthrough drug in neuroblastoma
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.